Severe disruptive behaviour disorder

Also known as: Severe Disruptive Behaviour Disorders

Drugs
Drugs and Targets

Drug	Drug Name	Drug Description
DB00502	Haloperidol	An antipsychotic agent used to treat schizophrenia and other psychoses, as well as symptoms of agitation, irritability, and delirium.

Drug	Drug Name	Target	Type
DB00502	Haloperidol	Dopamine D2 receptor	target
DB00502	Haloperidol	Glutamate receptor ionotropic, NMDA 2B	target
DB00502	Haloperidol	Dopamine D1 receptor	target
DB00502	Haloperidol	Cytochrome P450 1A2	enzyme
DB00502	Haloperidol	Cytochrome P450 2D6	enzyme
DB00502	Haloperidol	5-hydroxytryptamine receptor 2A	target
DB00502	Haloperidol	Dopamine D3 receptor	target
DB00502	Haloperidol	Cytochrome P450 3A4	enzyme
DB00502	Haloperidol	Cytochrome P450 3A5	enzyme
DB00502	Haloperidol	Cytochrome P450 3A7	enzyme
DB00502	Haloperidol	P-glycoprotein 1	transporter
DB00502	Haloperidol	Carbonyl reductase [NADPH] 1	enzyme
DB00502	Haloperidol	UDP-glucuronosyltransferase 1-9	enzyme
DB00502	Haloperidol	Cytochrome P450 2C19	enzyme
DB00502	Haloperidol	Cytochrome P450 2C9	enzyme
DB00502	Haloperidol	Melanin-concentrating hormone receptor 1	target
DB00502	Haloperidol	Synaptic vesicular amine transporter	target
DB00502	Haloperidol	5-hydroxytryptamine receptor 2C	target
DB00502	Haloperidol	Sigma non-opioid intracellular receptor 1	target
DB00502	Haloperidol	Histamine H1 receptor	target
DB00502	Haloperidol	Muscarinic acetylcholine receptor M3	target
DB00502	Haloperidol	Alpha-1A adrenergic receptor	target
DB00502	Haloperidol	Alpha-2A adrenergic receptor	target
DB00502	Haloperidol	Alpha-2B adrenergic receptor	target
DB00502	Haloperidol	Alpha-2C adrenergic receptor	target
DB00502	Haloperidol	5-hydroxytryptamine receptor 1A	target
DB00502	Haloperidol	5-hydroxytryptamine receptor 6	target
DB00502	Haloperidol	5-hydroxytryptamine receptor 7	target
DB00502	Haloperidol	Cytochrome P450 1A1	enzyme

Drug	Drug Name	Phase	Status	Count